Agenus (NASDAQ: AGEN)
Agenus Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Agenus Company Info
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
News & Analysis
Agenus Posts 48% Q2 Revenue Miss
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
This small-cap biotech stock is surging. Time to buy?
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
The company hopes to engineer a 1-for-20 reverse stock split.
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
These two biotech stocks could be poised for a trend reversal.
3 Magnificent Growth Stocks to Buy on the Dip
These three biotech stocks are attractive buys right now.
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months.
Valuation
Earnings Transcripts
Agenus (AGEN) Q4 2024 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2024.
Agenus (AGEN) Q3 2024 Earnings Call Transcript
AGEN earnings call for the period ending September 30, 2024.
Agenus (AGEN) Q2 2024 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2024.
Agenus (AGEN) Q1 2024 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.